KLP Kapitalforvaltning’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$52M Buy
104,741
+9,360
+10% +$4.15M 0.17% 108
2026
Q1
$42.6M Buy
95,381
+2,480
+3% +$1.16M 0.17% 111
2025
Q4
$42.1M Buy
92,901
+260
+0.3% +$112K 0.16% 115
2025
Q3
$36.3M Sell
92,641
-200
-0.2% -$83.6K 0.14% 133
2025
Q2
$41.3M Buy
92,841
+5,100
+6% +$2.35M 0.18% 108
2025
Q1
$42.5M Buy
87,741
+800
+0.9% +$373K 0.21% 95
2024
Q4
$35M Buy
+86,941
New +$40.3M 0.17% 113

Other funds holding VRTX

KLP Kapitalforvaltning's VRTX Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Vertex Pharmaceuticals (VRTX) stake by 9.8% in Q2 2026, buying an estimated $4.15M and bringing the position to 104,741 shares worth $52M. The position accounts for 0.17% of the portfolio, ranked #108.

KLP Kapitalforvaltning first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • KLP Kapitalforvaltning held 104,741 shares of Vertex Pharmaceuticals worth $52M as of Q2 2026.
  • KLP Kapitalforvaltning bought 9,360 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.15M.
  • Vertex Pharmaceuticals made up 0.17% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #108 holding.
  • KLP Kapitalforvaltning first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.